The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.
Welcome to The Lymphoma Channel
Mantle cell lymphoma (MCL) is relatively rare non-Hodgkin lymphoma (NHL) which accounts for ~6% of NHL.
Most MCLs arise from B cells in the mantle zone within a lymph node, and it is more often diagnosed in males than females (2:1 ratio), with the average age at diagnosis being mid-60s, and most patients presenting at later stages III–IV.
MCL is aggressive and incurable with an average overall survival of 2–4 years. It is associated with rapid progression, temporary response to chemotherapy and high recurrence rate.
Although there is no widely accepted first line therapy for MCL, aggressive chemo-immunotherapy regimens containing cytarabine and rituximab, followed by autologous stem cell transplantation and maintenance rituximab are most commonly used in young, fit patients. In older patients who are not eligible for transplantation, chemo-immunotherapy, followed by rituximab maintenance is most commonly used. Many clinical trials are underway to evaluate new therapies for the treatment of MCL, including immunomodulators, proteasome inhibitors, monoclonal antibodies and CAR-T therapy.